USPTO trademark

CUROSYGNAL

Opposition periodUSPTOWord markClass 9Class 42

"CUROSYGNAL" is a word mark owned by General Genomics Inc., filed at the USPTO on April 24, 2026. It is in its opposition period and covers classes 9 and 42.

Get this data via the API
Official USPTO record
CUROSYGNAL trademark as filed
As filed with the USPTO
Status
Opposition period
Since September 29, 2026
Filed
April 24, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99785464
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
2 classes
Ownership

Who owns CUROSYGNAL

The owner and representative on file with the office.

Owner

General Genomics Inc.

Oklahoma City, United States

Representative

N. Christopher Norton

ArentFox Schiff LLP

Goods and services

What the mark covers

The products and services CUROSYGNAL is filed for, grouped by Nice class.

  • Downloadable software for aggregating, normalizing, and analyzing healthcare-related data to identify, prioritize, and communicate clinical, operational, and financial risk indicators, for generating alerts, notifications, and workflow signals based on configurable rules and analytics models, for capturing, timestamping, categorizing, and tracking events, documentation status, and workflow activities in institutional healthcare environments, for producing dashboards, reports, and data visualizations; Downloadable software for for generating audit logs, data lineage records, and system-generated summaries for organizational oversight, for integrating data from electronic records systems and enterprise data sources, for integrating data from electronic records systems and enterprise data sources, configurable for deployment in on-premise, private cloud, and public cloud environments featuring authentication, SSO, and RBAC; Downloadable software for for identifying reimbursement-related variances, payer trends, and fiscal mapping outputs, excluding financial transaction processing and excluding direct medical diagnosis, treatment recommendations, and clinical care delivery

  • Software as a service (SAAS) services featuring software for aggregating, processing, and analyzing healthcare-related data to identify, prioritize, and communicate clinical, operational, and financial risk indicators; Software as a service (SAAS) services featuring software for generating alerts, notifications, and workflow signals based on configurable rules, thresholds, and analytics models; Software as a service (SAAS) services featuring software for tracking events, documentation status, and workflow activities within institutional healthcare environments; Software as a service (SAAS) services featuring software for generating audit trails, data lineage records, and performance reports for organizational oversight and compliance monitoring; Software as a service (SAAS) services featuring software for integrating data from electronic records systems and third-party data sources to provide dashboards, analytics, and visualization tools; Software as a service (SAAS) services featuring software for enabling secure user access through authentication mechanisms, including single sign-on (SSO), and role-based access control (RBAC); Software as a service (SAAS) services featuring software for deploying in private cloud, public cloud, and hybrid computing environments; Software as a service (SAAS) services featuring software for identifying reimbursement-related variances, payer-related trends, and fiscal mapping outputs through data analysis, excluding insurance administration, claims processing, financial transaction services, and excluding direct medical diagnosis, treatment recommendations, or clinical care delivery

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Official gazette publication confirmation e-mailed
  2. Published for opposition
  3. Notification of notice of publication e-mailed
  4. Approved for pub - principal register
  5. Assigned to examiner
  6. New application office supplied data entered
  7. Application filing receipt mailed
  8. New application entered
FAQ

About CUROSYGNAL

Who owns the trademark "CUROSYGNAL"?

The USPTO trademark "CUROSYGNAL" (application 99785464) is owned by General Genomics Inc.

What is the status of "CUROSYGNAL"?

Its status at the USPTO is: opposition period.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull CUROSYGNAL and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019dcc8e-570a-717a-a6d3-a0f5232a5620
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019dcc8e-570a-717a-a6d3-a0f5232a5620",
  "object": "trademark",
  "mark_text": "CUROSYGNAL",
  "status": {
    "primary": "pending",
    "stage": "pending_opposition"
  },
  "office_code": "US",
  "application_number": "99785464",
  "filing_date": "2026-04-24",
  "nice_classes": [
    9,
    42
  ],
  "owners": [
    {
      "name": "General Genomics Inc.",
      "entity_id": null
    }
  ]
}